Asthma - Versorgungsleitlinien.de

NVL Asthma, 2. Auflage
Langfassung
Juli 2011, Version 1.3
287. Cates CJ, Lasserson TJ, Jaeschke R. Regular treatment with salmeterol and inhaled steroids for
chronic asthma: serious adverse events. Cochrane Database Syst Rev 2009;(3):CD006922.
288. Cates CJ, Cates MJ, Lasserson TJ. Regular treatment with formoterol for chronic asthma:
serious adverse events. Cochrane Database Syst Rev 2008;(4):CD006923.
289. Cates CJ, Lasserson TJ, Jaeschke R. Regular treatment with formoterol and inhaled steroids for
chronic asthma: serious adverse events. Cochrane Database Syst Rev 2009;(2):CD006924.
290. Sears MR, Ottosson A, Radner F, Suissa S. Long-acting beta-agonists: a review of formoterol
safety data from asthma clinical trials. Eur Respir J 2009;33(1):21-32.
291. Kramer JM. Balancing the benefits and risks of inhaled long-acting beta-agonists--the influence
of values. N Engl J Med 2009;360(16):1592-5.
292. Chowdhury BA, Dal PG. The FDA and safe use of long-acting beta-agonists in the treatment of
asthma. N Engl J Med 2010;362(13):1169-71.
293. U.S. Food and Drug Administration (FDA). FDA Drug Safety Communication: New safety
requirements for long-acting inhaled asthma medications called Long-Acting Beta-Agonists
(LABAs). 2010 [cited: 2010 Nov 19]. Available from:
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProvi
ders/ucm200776.htm
294. U.S. Food and Drug Administration (FDA). FDA Drug Safety Communication: Drug labels now
contain updated recommendations on the appropriate use of long-acting inhaled asthma
medications called Long-Acting Beta-Agonists (LABAs). 2010 [cited: 2010 Nov 19].
Available from:
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProvi
ders/ucm213836.htm
295. Sears MR. Safety of long-acting beta-agonists: are new data really required? Chest
2009;136(2):604-7.
296. Weatherall M, Wijesinghe M, Perrin K, Harwood M, Beasley R. Meta-analysis of the risk of
mortality with salmeterol and the effect of concomitant inhaled corticosteroid therapy. Thorax
2010;65(1):39-43.
297. Salpeter SR, Wall AJ, Buckley NS. Long-acting beta-agonists with and without inhaled
corticosteroids and catastrophic asthma events. Am J Med 2010;123(4):322-8.
298. Stoloff SW, Stempel DA, Meyer J, Stanford RH, Carranza R, Jr. Improved refill persistence with
fluticasone propionate and salmeterol in a single inhaler compared with other controller
therapies. J Allergy Clin Immunol 2004;113(2):245-51.
299. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Fixe Kombinationen
aus Kortikosteroiden und lang wirksamen Beta-2-Rezeptoragonisten zur inhalativen
Anwendung bei Patienten mit Asthma bronchiale - Ergänzungsauftrag, Abschlussbericht.
Auftrag A07-01. Version 1.0. 2008 [cited: 2009 Okt 12]. Available from:
http://www.iqwig.de/download/A07-
01_Abschlussbericht_ICS_LABA_Fixkombinationen_bei_Asthma_bronchiale_Ergaenzungs
auftrag.pdf
300. Jenkins C, Kolarikova R, Kuna P, Caillaud D, Sanchis J, Popp W, Pettersson E. Efficacy and
safety of high-dose budesonide/formoterol (Symbicort) compared with budesonide
Gilt nur für
Erwachsene
Gilt nur für
Kinder/Jugendliche
Allgemeine
Empfehlungen
© 2009 221